In basal-like breast cancer, Epalrestat disrupted the Twist2–AKR1B1–NF-κB positive feedback loop, restored E-cadherin expression, reduced PGF2A production, and markedly suppressed cell migration, invasion, and lung metastasis in vivo [46]. The gene discussed is AKR1B1; the disease is breast cancer.